Steris Corporation
$514.3K 783 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Novartis Pharma AG
Novartis Pharma AG reported $513,494.97 across General Payments, Research, and Ownership to 73 physicians and teaching hospitals across 259 transactions.
- $513.5K Above-median payer
- All-tracks total
- 259 Above-median volume
- Transactions
- 73 Below-median reach
- Recipients
- −$148.5K
- General Payments vs PY2023
Novartis Pharma AG reported $513,494.97 across all CMS Open Payments tracks (General + Research + Ownership) to 73 physicians and teaching hospitals in Program Year 2024 - ranking #756 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $161,894.49, averaging $7.0K per recipient.
How Novartis Pharma AG's $513.5K all-tracks total breaks down
Novartis Pharma AG's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
22/100
Total payments
F
15/100
Transaction volume
F
12/100
Physician reach
F
11/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer novartis-pharma-ag Novartis Pharma AG
$513.5K · #756/1,925 · 0.0% industry · PY2024
- TOT $513.5K
- RANK #756
- SHARE 0.0%
- TXN 259
- RCP 73
- CAT 4
- GEN $161.9K
- ΔGEN −$148.5K
- TOP1 13.7%
- PY 2024
Volume peers
Nearest volume peer: Steris Corporation ($514.3K)
Novartis Pharma AG sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Novartis Pharma AG's CMS-reported General Payments decreased by $148.5K (−47.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: NOVARTIS PHARMA AGPY2023: NOVARTIS PHARMA AGPY2024: Novartis Pharma AG. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $310,413.09
- PY2024
- $161,894.49
What the Data Shows for Novartis Pharma AG
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Novartis Pharma AG, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Consulting Fee" leads the 4-category general-payment breakdown below at $141.9K (87.6% of General Payments, 46 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Consulting Fee" leads Novartis Pharma AG's 4-category general-payment breakdown at $141.9K, 87.6% of the reported total.
Novartis Pharma AG reports 4 general-payment categories - the top three are Consulting Fee (87.6%), Travel and Lodging (10.3%), and Education (1.8%). The remaining 1 category make up 0.3% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Novartis Pharma AG divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $141.9K | 46 | 87.6% |
| Travel and Lodging | $16.7K | 16 | 10.3% |
| Education | $2.9K | 3 | 1.8% |
| Food and Beverage | $432.70 | 8 | 0.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $71,097.67 (43.9%) of $161,894.49 in this company's General Payments records across 40 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Novartis Pharma AG
The five named recipients with the highest reported General Payments from this company
- 1
R Wright
$22,164.28 across 8 reported transactions
- 2
Dejan Juric
$15,648.68 across 5 reported transactions
- 3
Bipin Savani
$15,600.00 across 2 reported transactions
- 4
Amit Bar-Or
$9,115.94 across 4 reported transactions
- 5
Jorge E Cortes-Franco
$8,568.77 across 7 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Novartis Pharma AG ranks #756 of 1,925 by total payments (top 39% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,251 of 1,838 by HHI (bottom 32% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Nexxt Spine LLC : $292.8K total payments, HHI 576
- Solta Medical, a division of Bausch Health US, LLC : $585.9K total payments, HHI 572
- Bisco, Inc. : $180.9K total payments, HHI 571
- Gramercy Extremity Orthopedics LLC : $51.0K total payments, HHI 569
- LifeNet Health : $410.9K total payments, HHI 564
- Mindray DS USA, Inc. : $209.1K total payments, HHI 557
- Novartis Pharma AG (this company) : $161.9K total payments, HHI 557
- Trimed, Inc. : $1.0M total payments, HHI 556
- Upsher-Smith Laboratories LLC : $19.0K total payments, HHI 555
- Monaghan Medical Corporation : $16.0K total payments, HHI 555
- Cochlear Americas : $568.5K total payments, HHI 553
- Eitan Medical North America, Inc. : $1.6K total payments, HHI 552
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Novartis Pharma AG's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Novartis Pharma AG.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Novartis Pharma AG.
Showing 6 of 1,924 companies with CMS-reported payment data.
Thea Pharma Inc.
$512.0K 3,562 recipients
Compare payment profiles
Genetesis, Inc.
$515.3K 13 recipients
Compare payment profiles
Kestra Medical Technology Services, Inc.
$515.4K 13,441 recipients
Compare payment profiles
Painteq LLC
$516.0K 4,787 recipients
Compare payment profiles
Central Indiana URS Consumables, LLC
$507.6K 14 recipients
Compare payment profiles
Put this to use
Novartis Pharma AG ranks #756 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Novartis Pharma AG. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.